143 related articles for article (PubMed ID: 23648677)
1. UDP-glucuronosyltransferase 2B15 (UGT2B15) is the major enzyme responsible for sipoglitazar glucuronidation in humans: retrospective identification of the UGT isoform by in vitro analysis and the effect of UGT2B15*2 mutation.
Nishihara M; Hiura Y; Kawaguchi N; Takahashi J; Asahi S
Drug Metab Pharmacokinet; 2013; 28(6):475-84. PubMed ID: 23648677
[TBL] [Abstract][Full Text] [Related]
2. The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.
Stringer F; Scott G; Valbuena M; Kinley J; Nishihara M; Urquhart R
Eur J Clin Pharmacol; 2013 Mar; 69(3):423-30. PubMed ID: 22960998
[TBL] [Abstract][Full Text] [Related]
3. UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.
Court MH; Hao Q; Krishnaswamy S; Bekaii-Saab T; Al-Rohaimi A; von Moltke LL; Greenblatt DJ
J Pharmacol Exp Ther; 2004 Aug; 310(2):656-65. PubMed ID: 15044558
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9.
Court MH; Duan SX; Guillemette C; Journault K; Krishnaswamy S; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2002 Nov; 30(11):1257-65. PubMed ID: 12386133
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.
Stringer F; Ploeger BA; DeJongh J; Scott G; Urquhart R; Karim A; Danhof M
J Clin Pharmacol; 2013 Mar; 53(3):256-63. PubMed ID: 23444281
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10.
Watanabe Y; Nakajima M; Yokoi T
Drug Metab Dispos; 2002 Dec; 30(12):1462-9. PubMed ID: 12433820
[TBL] [Abstract][Full Text] [Related]
7. Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.
Hanioka N; Naito T; Narimatsu S
Chemosphere; 2008 Dec; 74(1):33-6. PubMed ID: 18990428
[TBL] [Abstract][Full Text] [Related]
8. Hepatic glucuronidation of 4-tert-octylphenol in humans: inter-individual variability and responsible UDP-glucuronosyltransferase isoforms.
Isobe T; Ohkawara S; Tanaka-Kagawa T; Jinno H; Hanioka N
Arch Toxicol; 2017 Nov; 91(11):3543-3550. PubMed ID: 28500425
[TBL] [Abstract][Full Text] [Related]
9. Identification of UDP-glucuronosyltransferases 1A1, 1A3 and 2B15 as the main contributors to glucuronidation of bakuchiol, a natural biologically active compound.
Li F; Wang S; Lu D; Wang Y; Dong D; Wu B
Xenobiotica; 2017 May; 47(5):369-375. PubMed ID: 27314830
[TBL] [Abstract][Full Text] [Related]
10. UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin.
Fujiwara R; Sumida K; Kutsuno Y; Sakamoto M; Itoh T
Drug Metab Pharmacokinet; 2015 Feb; 30(1):82-8. PubMed ID: 25760534
[TBL] [Abstract][Full Text] [Related]
11. A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.
Stringer F; DeJongh J; Scott G; Danhof M
J Clin Pharmacol; 2014 Apr; 54(4):453-61. PubMed ID: 24214217
[TBL] [Abstract][Full Text] [Related]
12. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin.
Hanioka N; Ozawa S; Jinno H; Ando M; Saito Y; Sawada J
Xenobiotica; 2001 Oct; 31(10):687-99. PubMed ID: 11695848
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of the microRNA response elements in the 3'-untranslated region of the UDP glucuronosyltransferase (UGT) 2B7 and 2B15 genes by a functional genomics approach.
Papageorgiou I; Court MH
Biochem Pharmacol; 2017 Dec; 146():199-213. PubMed ID: 28962835
[TBL] [Abstract][Full Text] [Related]
14. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.
He X; Hesse LM; Hazarika S; Masse G; Harmatz JS; Greenblatt DJ; Court MH
Br J Clin Pharmacol; 2009 Nov; 68(5):721-30. PubMed ID: 19916996
[TBL] [Abstract][Full Text] [Related]
15. The effect of valproic acid on drug and steroid glucuronidation by expressed human UDP-glucuronosyltransferases.
Ethell BT; Anderson GD; Burchell B
Biochem Pharmacol; 2003 May; 65(9):1441-9. PubMed ID: 12732356
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity.
Mutlib AE; Goosen TC; Bauman JN; Williams JA; Kulkarni S; Kostrubsky S
Chem Res Toxicol; 2006 May; 19(5):701-9. PubMed ID: 16696573
[TBL] [Abstract][Full Text] [Related]
17. Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation.
Lewis BC; Mackenzie PI; Elliot DJ; Burchell B; Bhasker CR; Miners JO
Biochem Pharmacol; 2007 May; 73(9):1463-73. PubMed ID: 17223084
[TBL] [Abstract][Full Text] [Related]
18. Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.
Court MH
Methods Enzymol; 2005; 400():104-16. PubMed ID: 16399346
[TBL] [Abstract][Full Text] [Related]
19. Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes.
Rouguieg K; Picard N; Sauvage FL; Gaulier JM; Marquet P
Drug Metab Dispos; 2010 Jan; 38(1):40-5. PubMed ID: 19841060
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
Innocenti F; Iyer L; RamÃrez J; Green MD; Ratain MJ
Drug Metab Dispos; 2001 May; 29(5):686-92. PubMed ID: 11302935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
